摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

O-环己基甲基-羟胺 | 110238-61-4

中文名称
O-环己基甲基-羟胺
中文别名
——
英文名称
O-(cyclohexylmethyl)hydroxylamine
英文别名
——
O-环己基甲基-羟胺化学式
CAS
110238-61-4
化学式
C7H15NO
mdl
——
分子量
129.202
InChiKey
ZVLSNSQXNJVHMG-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.7
  • 重原子数:
    9
  • 可旋转键数:
    2
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    1.0
  • 拓扑面积:
    35.2
  • 氢给体数:
    1
  • 氢受体数:
    2

安全信息

  • 海关编码:
    2922199090

SDS

SDS:791eb0d9b8809fc39a7afaa9432e3404
查看

反应信息

  • 作为反应物:
    描述:
    O-环己基甲基-羟胺吡啶4-二甲氨基吡啶一水合肼三乙胺三苯基膦 作用下, 以 乙醇二氯甲烷氯仿 为溶剂, 反应 24.17h, 生成 6-(2-cyano-1-(pyridin-4-yl)guanidino)-N-(cyclohexylmethoxy)-N-(2-fluoroethyl)hexane-1-sulfonamide
    参考文献:
    名称:
    Nicotinamide Phosphoribosyltransferase Inhibitors, Design, Preparation, and Structure–Activity Relationship
    摘要:
    Existing pharmacological inhibitors for nicotinamide phosphoribosyltransferase (NAMPT) are promising therapeutics for treating cancer. By using medicinal and computational chemistry methods, the structure-activity relationship for novel classes of NAMPT inhibitors is described, and the compounds are optimized. Compounds are designed inspired by the NAMPT inhibitor APO866 and cyanoguanidine inhibitor scaffolds. In comparison with recently published derivatives, the new analogues exhibit an equally potent antiproliferative activity in vitro and comparable activity in vivo. The best performing compounds from these series showed subnanomolar antiproliferative activity toward a series of cancer cell lines (compound 15: IC50 0.025 and 0.33 nM, in A2780 (ovarian carcinoma) and MCF-7 (breast), respectively) and potent antitumor in vivo activity in well-tolerated doses in a xenograft model. In an A2780 xenograft mouse model with large tumors (500 mm(3)), compound 15 reduced the tumor volume to one-fifth of the starting volume at a dose of 3 mg/kg administered ip, bid, days 1-9. Thus, compounds found in this study compared favorably with compounds already in the clinic and warrant further investigation as promising lead molecules for the inhibition of NAMPT.
    DOI:
    10.1021/jm4009949
  • 作为产物:
    参考文献:
    名称:
    Parasiticidal 2-alkoxy- and 2-aryloxyiminoalkyl trifluoromethanesulfonanilides
    摘要:
    A series of novel 2-alkoxy- and 2-aryloxyiminoalkyl trifluoromethanesulfonanilide derivatives have shown significant in vitro parasiticidal activity against the ectoparasites Ctenocephalides felis and Rhipicephalus sanguineus. A number of these compounds also displayed significant in vitro endoparasite activity against the nematode Haemonchus contortus. Crown copyright (C) 2007 Published by Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmcl.2007.10.090
点击查看最新优质反应信息

文献信息

  • [EN] PYRIDINYL DERIVATIVES AS INHIBITORS OF ENZYME NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE<br/>[FR] DÉRIVÉS DE PYRIDINYLE UTILISÉS EN TANT QU'INHIBITEURS DE L'ENZYME NICOTINAMIDE PHOSPHORIBOSYLTRANSFÉRASE
    申请人:TOPOTARGET AS
    公开号:WO2010142735A1
    公开(公告)日:2010-12-16
    The present application discloses a compound of the formula (I) wherein Q is optionally substituted pyridyl; p is 0-6; Y is formulae (i), (ii) and (iii) where X is =O, =S and =N-CN, r is 1-12, R is -Z-A, Z is a single bond, -S(=O)2-, >P=O, >C=O, -C(=O)NH-, and -C(=S)NH-; and A is hydrogen, C1-12-alkyl, C3-12-cycloalkyl, - [CH2CH2O]1-10-(C1-6-alkyl), C1-12-alkenyl, aryl, heterocyclyl, and heteroaryl; B is a single bond, -NRN-, -S(=O)2- and -O-; wherein RN is selected from hydrogen, C1-12-alkyl, C3-12-cycloalkyl, -[CH2CH2O]1-10-(C1-6-alkyl), C1-12-alkenyl, aryl, heterocyclyl, and heteroaryl; s is 0-6; and Cy is aryl, cycloalkyl, heterocyclyl, and heteroaryl. The compounds are usefuld for use as a medicament for the treatment of a disease or a condition caused by an elevated level of nicotinamide phosphoribosyltransferase (NAMPRT).
    本申请公开了一种化合物,其化学式为(I),其中Q是可选择取代的吡啶基;p为0-6;Y是式(i)、(ii)和(iii),其中X为=O、=S和=N-CN,r为1-12,R为-Z-A,Z为单键,-S(=O)2-,>P=O,>C=O,-C(=O)NH-和-C(=S)NH-;A为氢、C1-12-烷基、C3-12-环烷基、-[CH2CH2O]1-10-(C1-6-烷基)、C1-12-烯基、芳基、杂环烷基和杂芳基;B为单键,-NRN-,-S(=O)2-和-O-;其中RN从氢、C1-12-烷基、C3-12-环烷基、-[CH2CH2O]1-10-(C1-6-烷基)、C1-12-烯基、芳基、杂环烷基和杂芳基中选择;s为0-6;Cy为芳基、环烷基、杂环烷基和杂芳基。这些化合物可用作治疗由烟酰胺磷酸核糖转移酶(NAMPRT)水平升高引起的疾病或症状的药物。
  • Hydrazide and alkoxyamide angiogenesis inhibitors
    申请人:——
    公开号:US20020002152A1
    公开(公告)日:2002-01-03
    Compounds having the formula 1 are methionine aminopeptidase type 2 (MetAP2) inhibitors and are useful for inhibiting angiogenesis. Also disclosed are MetAP2-inhibiting compositions and methods of inhibiting angiogenesis in a mammal.
    具有以下化学式的化合物是蛋氨酸氨肽酶2型(MetAP2)抑制剂,对抑制血管生成有用。还公开了抑制MetAP2的组合物和在哺乳动物中抑制血管生成的方法。
  • [EN] NOVEL CYANOGUANIDINES<br/>[FR] NOUVELLES CYANOGUANIDINES
    申请人:TOPOTARGET AS
    公开号:WO2009086835A1
    公开(公告)日:2009-07-16
    This application discloses novel cyanoguanidines of the formula (I) wherein A is selected from -C(=O)-, -S(=O)2-, -C(=S)-, and -P(=O)(R5)-, wherein R5 is selected from C1-6-alkyl, C1-6-alkoxy, and hydroxy; B is selected from a single bond, -O-, -NR6- and -C(=O)-NR6-, wherein R6 is selected from hydrogen, optionally substituted C1-12-alkyl, optionally substituted C1-12-alkenyl, optionally substituted aryl, optionally substituted heterocyclyl, and optionally substituted heteroaryl; and m is an integer of 0-12 and n is an integer of 0-12, wherein the sum m+n is 1-20; and R1 is selected from optionally substituted heteroaryl; and pharmaceutically acceptable salts thereof, and prodrugs thereof. The compounds are usefuld for use as a medicament for the treatment of a disease or a condition caused by an elevated level of nicotinamide phosphoribosyltransferase (NAMPRT).
    该申请公开了一种新型氰胍啶化合物,其化学式为(I),其中A从-C(=O)-,-S(=O)2-,-C(=S)-和-P(=O)(R5)-中选择,其中R5选择自C1-6-烷基,C1-6-烷氧基和羟基;B从单键,-O-,-NR6-和-C(=O)-NR6-中选择,其中R6选择自氢,可选择地取代的C1-12-烷基,可选择地取代的C1-12-烯基,可选择地取代的芳基,可选择地取代的杂环烷基和可选择地取代的杂环芳基;m为0-12的整数,n为0-12的整数,其中m+n之和为1-20;R1选择自可选择地取代的杂环芳基;以及其药学上可接受的盐和前药。这些化合物可用作治疗由烟酰胺磷酸核糖转移酶(NAMPRT)水平升高引起的疾病或病况的药物。
  • Synthesis and antiviral activities of novel N-alkoxy-arylsulfonamide-based HIV protease inhibitors
    作者:Ronald G. Sherrill、Eric S. Furfine、Richard J. Hazen、John F. Miller、David J. Reynolds、Douglas M. Sammond、Andrew Spaltenstein、Pat Wheelan、Lois L. Wright
    DOI:10.1016/j.bmcl.2005.05.101
    日期:2005.8
    A series of novel N-alkoxy-arylsulfonamide HIV protease inhibitors with low picomolar enzyme activity and single digit nanomolar antiviral activity is disclosed.
    公开了一系列具有低皮摩尔酶活性和一位数纳摩尔抗病毒活性的新颖的N-烷氧基-芳基磺酰胺HIV蛋白酶抑制剂。
  • NOVEL VASCULAR LEAKAGEAGE INHIBITOR
    申请人:Industry-Academic Cooperation Foundation, Yonsei University
    公开号:US20140378399A1
    公开(公告)日:2014-12-25
    The present disclosure relates to a novel vascular leakage inhibitor. The novel vascular leakage inhibitor of the present invention inhibits the apoptosis of vascular endothelial cells, inhibits the formation of actin stress fibers induced by VEGF, and enhances the cortical actin ring structure, thereby inhibiting vascular leakage. Accordingly, the vascular leakage inhibitor of the present invention can prevent or treat various diseases caused by vascular leakage. Since the vascular leakage inhibitor of the present invention is synthesized from commercially available or easily synthesizable pregnenolones, it has remarkably superior feasibility of commercial synthesis.
    本公开涉及一种新型血管渗漏抑制剂。本发明的新型血管渗漏抑制剂抑制血管内皮细胞凋亡,抑制由VEGF诱导的肌动蛋白应激纤维的形成,并增强皮质肌动蛋白环结构,从而抑制血管渗漏。因此,本发明的血管渗漏抑制剂可以预防或治疗由血管渗漏引起的各种疾病。由于本发明的血管渗漏抑制剂是由商业可获得或易于合成的孕酮合成的,因此具有明显优越的商业合成可行性。
查看更多